Cargando…

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis

SIMPLE SUMMARY: Tucatinib is recommended by different guidelines as a third line of treatment in HER2(+) breast cancer. Although it is an effective treatment, different studies have highlighted that the high price of the drug makes it a not cost-effective treatment option. Therefore, this study aime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antonazzo, Ippazio Cosimo, Cortesi, Paolo Angelo, Miceli Sopo, Gerardo, Mazzaglia, Giampiero, Conte, Pierfranco, Mantovani, Lorenzo Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953803/ https://www.ncbi.nlm.nih.gov/pubmed/36831518 http://dx.doi.org/10.3390/cancers15041175

Ejemplares similares

Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

Statins Use in Patients with Cardiovascular Diseases and COVID-19 Outcomes: An Italian Population-Based Cohort Study
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2021)

A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy
por: Zambelli, Alberto, et al.
Publicado: (2023)

Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

Time trends in the incidence of essential tremor: Evidences from UK and France primary care data
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

Azithromycin use and outcomes in patients with COVID-19: an observational real-world study
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2022)

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
por: Ulrich, Lara, et al.
Publicado: (2021)

Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer
por: Corti, C., et al.
Publicado: (2021)

The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer
por: Sirhan, Zaid, et al.
Publicado: (2022)

Combination of tucatinib and neural stem cells secreting anti-HER2 antibody prolongs survival of mice with metastatic brain cancer
por: Cordero, Alex, et al.
Publicado: (2021)

Real-world patient characteristics, treatment patterns, and clinical outcomes associated with tucatinib therapy in HER2-positive metastatic breast cancer
por: Kaufman, Peter A., et al.
Publicado: (2023)

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2022)

Effect of Tucatinib on Cardiac Repolarization in Healthy Volunteers
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2023)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer From the US and Chinese Perspectives
por: Wu, Qiuji, et al.
Publicado: (2020)

Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973)
por: Cortesi, Paolo Angelo, et al.
Publicado: (2022)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

LMAP-15 INTRACRANIAL RADIOTHERAPY WITH TUCATINIB FOR BRAIN METASTASIS FROM HER2-POSITIVE BREAST CANCER: A SINGLE-INSTITUTION SERIES
por: Khatri, Vaseem, et al.
Publicado: (2023)

Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres
por: Berardi, Lorenzo, et al.
Publicado: (2019)

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
por: Lin, Nancy U., et al.
Publicado: (2022)

Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers
por: Topletz-Erickson, Ariel, et al.
Publicado: (2022)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up—Reply
por: Ferrara, Pietro, et al.
Publicado: (2022)

Editorial: Overcoming boundaries in public health: Advances in international and global health
por: Antonazzo, Ippazio C., et al.
Publicado: (2022)

KRAS Early Testing: Consensus Initiative and Cost-Effectiveness Evaluation for Metastatic Colorectal Patients in an Italian Setting
por: Barone, Carlo, et al.
Publicado: (2014)

Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects
por: Topletz‐Erickson, Ariel R., et al.
Publicado: (2020)

Evaluation of the inhibitory effect of quercetin on the pharmacokinetics of tucatinib in rats by a novel UPLC–MS/MS assay
por: Zhang, Ying, et al.
Publicado: (2022)

Prevalence and Determinants of Long-Term Utilization of Antidepressant Drugs: A Retrospective Cohort Study
por: Lunghi, Carlotta, et al.
Publicado: (2020)

Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up
por: Ponticelli, Domenico, et al.
Publicado: (2021)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

Raphanus sativus cv. Sango Sprout Juice Decreases Diet-Induced Obesity in Sprague Dawley Rats and Ameliorates Related Disorders
por: Vivarelli, Fabio, et al.
Publicado: (2016)

Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity
por: Alsalme, Ali, et al.
Publicado: (2020)

Long COVID Syndrome: Lesson Learned and Future Implications
por: Mazzaglia, Giampiero
Publicado: (2023)

Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment
por: Cortesi, Paolo Angelo, et al.
Publicado: (2017)

In vitro and ex vivo anti-tumor effect and mechanism of Tucatinib in leukemia stem cells and ABCG2-overexpressing leukemia cells
por: Jing, Wen, et al.
Publicado: (2021)

Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer
por: Buja, Alessandra, et al.
Publicado: (2022)

Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis
por: Schettini, Francesco, et al.
Publicado: (2021)

The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies
por: Ferrara, Pietro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bo8jm6iljmfe5oq79099diq3lk